Avalo Therapeutics (NASDAQ:AVTX) Shares Down 8.2% – Time to Sell?

Avalo Therapeutics, Inc. (NASDAQ:AVTX)’s stock price traded down 8.2% during mid-day trading on Wednesday . The company traded as low as $18.24 and last traded at $18.0880. 461,480 shares were traded during trading, a decline of 59% from the average session volume of 1,137,270 shares. The stock had previously closed at $19.71.

Wall Street Analysts Forecast Growth

Several research firms have commented on AVTX. Citizens Jmp dropped their target price on Avalo Therapeutics from $62.00 to $55.00 and set a “market outperform” rating on the stock in a report on Thursday, May 14th. Leerink Partners initiated coverage on Avalo Therapeutics in a research report on Monday, July 6th. They issued an “outperform” rating and a $38.00 price target for the company. Wall Street Zen upgraded shares of Avalo Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. BTIG Research reissued a “buy” rating and set a $58.00 price objective on shares of Avalo Therapeutics in a research report on Tuesday, June 16th. Finally, HC Wainwright reduced their price objective on shares of Avalo Therapeutics from $35.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Avalo Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.10.

Avalo Therapeutics Price Performance

The company has a market capitalization of $930.48 million, a PE ratio of -3.96 and a beta of 0.78. The firm has a 50-day moving average of $19.13 and a 200 day moving average of $17.06.

Avalo Therapeutics (NASDAQ:AVTX) last issued its earnings results on Thursday, August 6th. The company reported ($0.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.25). Equities analysts expect that Avalo Therapeutics, Inc. will post -2.69 EPS for the current year.

Insider Activity at Avalo Therapeutics

In other news, insider Mittie Doyle sold 1,450 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $18.00, for a total transaction of $26,100.00. Following the completion of the transaction, the insider directly owned 51,776 shares of the company’s stock, valued at $931,968. The trade was a 2.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 3,129 shares of company stock valued at $59,680 in the last three months. Insiders own 4.46% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Boothbay Fund Management LLC bought a new stake in Avalo Therapeutics in the 2nd quarter worth approximately $56,000. Dimensional Fund Advisors LP bought a new position in shares of Avalo Therapeutics during the 3rd quarter valued at $143,000. AlphaCentric Advisors LLC bought a new position in shares of Avalo Therapeutics during the 1st quarter valued at $174,000. California State Teachers Retirement System purchased a new position in shares of Avalo Therapeutics in the 2nd quarter worth $196,000. Finally, Jump Financial LLC purchased a new position in shares of Avalo Therapeutics in the 4th quarter worth $238,000. Institutional investors own 87.06% of the company’s stock.

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.